September 17, 2021

Cabometyx® (cabozantinib) is now U.S. FDA approved for to treat patients at least 12 years old who are radioactive iodine-refractory (unresponsive to treatment) or ineligible and have locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy.

  • First FDA-approved in 2012, Cabometyx is also indicated to treat renal cell carcinoma and hepatocellular carcinoma in patients who meet certain
  • Recommended dosing under the DTC indication is 40mg once daily for pediatric patients who have a body surface area of less than 1.2m2 and 60mg once daily for all other DTC
  • Manufactured by Exelixis, , Cabometyx is an oral tablet that should be taken at least one hour before and two hours after eating.
September 21, 2021

FDA Approves Ophthalmic Biosimilar Byooviz

Read More
September 17, 2021

Cabometyx Now Indicated to Treat Common Form of Thyroid Cancer

Read More
September 16, 2021

New Lung Cancer Drug Exkivity Receives FDA Approval

Read More
September 16, 2021

Two-Drug Therapy Authorized for COVID-19 Post-Exposure Prevention

Read More